Trial reportEmerging microbes & infections2026
Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses.
Trial report in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06457477 (The Safety and Efficacy of Sequential Combination Therapy With PD-1 Antibody and Pegylated Interferon-α in NA-supressed Chronic Hepatitis B Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Sequential Combination Therapy With PD-1 Antibody and Pegylated Interferon-α in NA-supressed Chronic Hepatitis B Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pegylated interferon-α (PEG-IFNα) exhibits suboptimal efficacy in achieving a functional cure in patients with chronic hepatitis B (CHB), partially due to impaired hepatitis B virus (HBV)-specific T-cell function. We conducted a pilot study (ClinicalTrials.gov: NCT06457477) to explore the efficacy, safety, and immunological changes associated with a response-guided sequential strategy of anti-PD-1 antibody (αPD-1) and PEG-IFNα. Ten virologically suppressed CHB patients receiving nucleos(t)ide analogues (NAs), all of whom had previously received PEG-IFNα and had HBsAg levels ≤200 IU/mL at enrolment, were included. The patients continued background NA therapy and received αPD-1 (sintilimab) for up to 24 weeks; PEG-IFNα was added at week 12 if HBsAg decline was <1 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.